Milestone Pharmaceuticals Inc. (MIST): Price and Financial Metrics
GET POWR RATINGS... FREE!
MIST Stock Price Chart Interactive Chart >
MIST Price/Volume Stats
| Current price | $3.83 | 52-week high | $9.85 |
| Prev. close | $3.90 | 52-week low | $3.10 |
| Day low | $3.72 | Volume | 130,500 |
| Day high | $4.00 | Avg. volume | 171,907 |
| 50-day MA | $3.59 | Dividend yield | N/A |
| 200-day MA | $5.56 | Market Cap | 131.32M |
Milestone Pharmaceuticals Inc. (MIST) Company Bio
Milestone Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. It designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.
Latest MIST News From Around the Web
Below are the latest news stories about MILESTONE PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MIST as an investment opportunity.
Milestone Pharmaceuticals GAAP EPS of -$0.31, revenue of $3.5M
|
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Corporate UpdateMilestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a clinical and corporate update. |
Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVTMilestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has entered into a $125 million strategic funding agreement with existing shareholder, RTW Investments, LP and certain of its affiliates ("RTW"). Proceeds from this tailored financing, together with $64.6 million of cash, cash equivalents and short-term investments as of December 31, 2022, are expected to fund |
Milestone Pharmaceuticals Progresses Clinical and Regulatory Activities for Etripamil in Patients with Paroxysmal Supraventricular TachycardiaMilestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced significant progress in clinical and regulatory activities for etripamil, the Company's investigational calcium channel blocker that is administered by patients outside of the healthcare setting to treat paroxysmal supraventricular tachycardia (PSVT). |
Milestone Pharmaceuticals to Present at Upcoming Investor ConferencesMilestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will present at the following investor conferences: |
MIST Price Returns
| 1-mo | 21.97% |
| 3-mo | -3.28% |
| 6-mo | -58.32% |
| 1-year | -40.34% |
| 3-year | 108.15% |
| 5-year | N/A |
| YTD | -3.28% |
| 2022 | -39.54% |
| 2021 | -2.24% |
| 2020 | -58.15% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...